-
Je něco špatně v tomto záznamu ?
Hepatic arterial infusion in liver tumors of unknown, uncertain or unusual primary: single-center experience
B. Melichar, J. Dvorak, K. Kamaradova, A. Krajina, H. Studentova,
Jazyk angličtina Země Řecko
Typ dokumentu klinické zkoušky, časopisecké články
PubMed
30941963
Knihovny.cz E-zdroje
- MeSH
- arteria hepatica * MeSH
- dospělí MeSH
- fluoruracil aplikace a dávkování MeSH
- intraarteriální infuze * MeSH
- leukovorin aplikace a dávkování MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- nádory jater farmakoterapie mortalita sekundární MeSH
- nádory farmakoterapie mortalita patologie MeSH
- následné studie MeSH
- prognóza MeSH
- protokoly protinádorové kombinované chemoterapie aplikace a dávkování MeSH
- retrospektivní studie MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
PURPOSE: The aim of the present study was to analyze a single-center experience with hepatic arterial infusion (HAI) in patients with unknown or uncertain primary or tumors not usually treated with HAI. METHODS: A retrospective analysis of 14 patients treated between 1996 and 2003 for liver tumors of unknown, uncertain or unusual primary was performed. RESULTS: All patients were treated with HAI combination regimens based on 5-fluorouracil and folinic acid. The response was not evaluable in most patients, predominantly because of only a single course of therapy could be administered and no cases of partial or complete response were noted. The median survival of all patients was 6.6 months (5-year survival 14%). CONCLUSION: The present data demonstrate limited efficacy of HAI in patients with liver tumors of unknown, uncertain or unusual primary. HAI should not be offered to these patients.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19034667
- 003
- CZ-PrNML
- 005
- 20191008124854.0
- 007
- ta
- 008
- 191007s2019 gr f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)30941963
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Melichar, Bohuslav $u Fourth Department of Medicine, Charles University Medical School Teaching Hospital, Hradec Kralove, Czech Republic.
- 245 10
- $a Hepatic arterial infusion in liver tumors of unknown, uncertain or unusual primary: single-center experience / $c B. Melichar, J. Dvorak, K. Kamaradova, A. Krajina, H. Studentova,
- 520 9_
- $a PURPOSE: The aim of the present study was to analyze a single-center experience with hepatic arterial infusion (HAI) in patients with unknown or uncertain primary or tumors not usually treated with HAI. METHODS: A retrospective analysis of 14 patients treated between 1996 and 2003 for liver tumors of unknown, uncertain or unusual primary was performed. RESULTS: All patients were treated with HAI combination regimens based on 5-fluorouracil and folinic acid. The response was not evaluable in most patients, predominantly because of only a single course of therapy could be administered and no cases of partial or complete response were noted. The median survival of all patients was 6.6 months (5-year survival 14%). CONCLUSION: The present data demonstrate limited efficacy of HAI in patients with liver tumors of unknown, uncertain or unusual primary. HAI should not be offered to these patients.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $7 D000971
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fluoruracil $x aplikace a dávkování $7 D005472
- 650 _2
- $a následné studie $7 D005500
- 650 12
- $a arteria hepatica $7 D006499
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a intraarteriální infuze $7 D007261
- 650 _2
- $a leukovorin $x aplikace a dávkování $7 D002955
- 650 _2
- $a nádory jater $x farmakoterapie $x mortalita $x sekundární $7 D008113
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nádory $x farmakoterapie $x mortalita $x patologie $7 D009369
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dvorak, Josef
- 700 1_
- $a Kamaradova, Katerina
- 700 1_
- $a Krajina, Antonín
- 700 1_
- $a Studentova, Hana
- 773 0_
- $w MED00005361 $t Journal of B.U.ON. : official journal of the Balkan Union of Oncology $x 2241-6293 $g Roč. 24, č. 1 (2019), s. 143-149
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30941963 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191008125311 $b ABA008
- 999 __
- $a ok $b bmc $g 1451327 $s 1073217
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 24 $c 1 $d 143-149 $e - $i 2241-6293 $m Journal of Balkan Union of Oncology $n J BUON $x MED00005361
- LZP __
- $a Pubmed-20191007
